{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/prostate-cancer/diagnosis/confirming-diagnosis-in-secondary-care/","result":{"pageContext":{"chapter":{"id":"8fdd4166-47a6-5d1b-b573-bb1ab5d09da8","slug":"confirming-diagnosis-in-secondary-care","fullItemName":"Confirming diagnosis in secondary care","depth":2,"htmlHeader":"<!-- begin field 16a37d01-c38c-4910-8f0c-b76540145840 --><h2>What investigations may be performed in secondary care?</h2><!-- end field 16a37d01-c38c-4910-8f0c-b76540145840 -->","summary":"","htmlStringContent":"<!-- begin item af3fa322-689b-49bf-b2b3-eb1b0f61c868 --><!-- begin field 1248c44a-9cd7-473a-bee8-363279551921 --><ul><li>In secondary care, a man with suspected prostate cancer may be offered a prostate biopsy to confirm or exclude the diagnosis, and imaging to assess the stage of the prostate cancer.</li><li><strong>Transrectal ultrasound (TRUS) </strong><ul><li>This may be used to examine the prostate and determine its size — it is not reliable enough to exclude prostate cancer. </li></ul></li><li><strong>TRUS prostate biopsy</strong></li><li>A raised PSA level alone may not automatically lead to a prostate biopsy. Other factors which will be considered include:<ul><li>Prostate size.</li><li>Digital rectal examination (DRE) findings.</li><li>Age.</li><li>Ethnicity</li><li>Family history of prostate cancer</li><li>Body weight/BMI.</li><li>Co-morbidities.</li><li>Previous history of negative biopsy, or PSA levels.</li></ul></li><li>A TRUS biopsy takes around 10-12 cores of prostatic tissue through the rectum, guided by ultrasound.  <ul><li>Additional biopsies may be taken if a lesion is found on ultrasound. </li></ul></li><li>If a tumour is detected, histology reveals how well it is differentiated and this is graded by the Gleason score.<ul><li>Up to 45% of tumours are missed at biopsy. </li></ul></li><li><strong>Additional Imaging</strong><ul><li>Multiparametric magnetic resonance imaging (mpMRI), and radioisotope bone scans may be used to assess the prostate gland and determine the extent of locally invasive cancer or presence of distant metastases.<ul><li>Diagnosis and staging of prostate cancer may be improved with mpMRI, before TRUS prostate biopsy.</li></ul></li></ul></li></ul><!-- end field 1248c44a-9cd7-473a-bee8-363279551921 --><!-- end item af3fa322-689b-49bf-b2b3-eb1b0f61c868 -->","topic":{"id":"2ab521f2-aa56-5e1e-b28e-fc4d637a303c","topicId":"1506c25e-8998-42e4-82c0-6b38dc3a1e9f","topicName":"Prostate cancer","slug":"prostate-cancer","lastRevised":"Last revised in October 2017","chapters":[{"id":"324faedd-14d8-5d99-8059-d9428da432ea","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"276607b5-8522-5d5e-86f1-d9be97d83a94","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"df8fe922-4f04-5594-b4a9-fc0935cf3b16","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d95f0cd5-43fd-5950-b45a-5d312e16b3e3","slug":"changes","fullItemName":"Changes"},{"id":"dc0f462f-4d9f-503f-ae6e-64aa386af1e8","slug":"update","fullItemName":"Update"}]},{"id":"fb4bea73-b877-5f11-9f5e-f4b1a776c6ab","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d9df68e4-4518-5224-b388-b610695e181f","slug":"goals","fullItemName":"Goals"},{"id":"cbda6200-7ae0-5f80-b984-4f2e0d78d4de","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b6c612ea-8423-5c36-abab-32784d6ed762","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4909e587-a937-5829-873f-b3e02e5c8a36","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"b3baf3db-45b6-5fd4-94e3-cbbaf8d70bd9","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d0703c17-2896-5c8e-a091-a6024da2508d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b6a5e49a-643a-5e4a-a980-dc835d73c66d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"7fb66c84-18e5-52f1-b7ef-daf96c4f903c","slug":"definition","fullItemName":"Definition"},{"id":"ae301838-d2bd-55ed-a057-844f73f6942a","slug":"causes","fullItemName":"Causes"},{"id":"5656e958-479a-5103-96a1-2b0d6c62c156","slug":"prevalence","fullItemName":"Prevalence"},{"id":"49f9ec22-1376-50e7-8891-e6050fbb5069","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"cf644b3b-5878-59e9-9641-63847a7f0cb5","slug":"prognosis","fullItemName":"Prognosis"},{"id":"511452bc-068d-5f51-b489-9e89b4396cd2","slug":"complications","fullItemName":"Complications"}]},{"id":"6c4ca641-81fa-53e0-8562-431396232bd7","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"7e53b66c-2f4f-500c-a8c0-9092cbce65bf","slug":"overview","fullItemName":"Overview"},{"id":"5e184056-05a4-5462-80be-51f03c9c94a2","slug":"signs-symptoms","fullItemName":"Signs and symptoms"},{"id":"5f6622b7-59bf-51f5-b413-1f0ec1a4b8d1","slug":"psa-testing","fullItemName":"PSA testing"},{"id":"30dc380e-addd-57b7-a015-a1b250c58b3c","slug":"digital-rectal-examination","fullItemName":"Digital rectal examination"},{"id":"509e34cf-6a18-526e-a3f0-d219fa4030de","slug":"when-to-refer","fullItemName":"When to refer"},{"id":"8fdd4166-47a6-5d1b-b573-bb1ab5d09da8","slug":"confirming-diagnosis-in-secondary-care","fullItemName":"Confirming diagnosis in secondary care"}]},{"id":"9dc72b4c-cd09-5f23-b45c-6d0306fa66dc","fullItemName":"Management","slug":"management","subChapters":[{"id":"56e2a92b-f611-57ed-91c6-f6672b72750f","slug":"management","fullItemName":"Scenario: Management"},{"id":"6cf2bc9c-e41d-5e71-b490-a48c7fa4a38b","slug":"complications-adverse-effects","fullItemName":"Scenario: Complications and adverse effects"}]},{"id":"742a5289-99d4-5d61-a8c9-7fc8409f0f23","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"5009abfd-1456-55b3-844d-23b74552f90c","slug":"medroxyprogesterone-acetate","fullItemName":"Medroxyprogesterone acetate"},{"id":"80712d44-9544-56aa-aa10-d4cd640429de","slug":"cyproterone-acetate","fullItemName":"Cyproterone acetate"}]},{"id":"7bed120a-c6b8-5f7e-941d-751749f78c0e","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"1c5c0083-b591-5115-8039-cdc5113cc070","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"6562ed52-3498-5877-b63d-7bb4a7b2656a","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"e27e1bd1-e689-5a6c-a6e5-36b9fcad98a3","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1d7864fd-9f5c-5976-a1b8-9df023b04f7e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e6798a57-1676-5675-b1a1-50a69534adff","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"67b2f477-e9ac-5da3-a8ab-5544ec9d70f3","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"812bede6-3d25-5e1d-ba87-ac56af0e611f","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"6c4ca641-81fa-53e0-8562-431396232bd7","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"5257b3e6-a391-5e61-9966-cd663158a910","slug":"basis-for-recommendation-618","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 60e513eb-0320-4cca-b3fc-28a4a339cf3a --><h3>Basis for recommendation</h3><!-- end field 60e513eb-0320-4cca-b3fc-28a4a339cf3a -->","summary":null,"htmlStringContent":"<!-- begin item 61842ab8-39b8-4179-bb49-6fa4a8997149 --><!-- begin field aec11f66-dbcd-47fb-9bd7-fe54e5251edd --><p>This information is based on the National Institute for Health and Care Excellence (NICE) guideline <em>Prostate cancer: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">NICE, 2014</a>] and the Public Health England (PHE) guidance <em>Prostate cancer risk management programme (PCRMP): benefits and risks of PSA testing</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">PHE, 2016</a>]. </p><h4>Transrectal ultrasound (TRUS) biopsy false negatives</h4><ul><li>False negative rates associated with TRUS biopsy can be as high as 45% [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">PHE, 2016</a>].</li><li>NICE recommends that for men with a negative TRUS biopsy, multiparametric MRI (mpMRI) is considered to determine whether a further biopsy is required [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">NICE, 2014</a>]. </li><li>Triage of men with clinical suspicion of prostate cancer (elevated prostate specific-antigen [PSA] and abnormal digital rectal examination [DRE]) to mpMRI prior to prostate biopsy could allow more specific selection of those men with clinically significant cancer which may require treatment. PHE suggests that 'this strategy could reduce the number of men with clinically insignificant disease who undergo unnecessary biopsy and treatment. This would also reduce the rate of complications that could interfere with accurate disease staging and improve disease risk stratification to manage appropriate treatment with active surveillance or radical therapies' [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">PHE, 2016</a>].</li></ul><!-- end field aec11f66-dbcd-47fb-9bd7-fe54e5251edd --><!-- end item 61842ab8-39b8-4179-bb49-6fa4a8997149 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}